The FDA has approved Astellas’s zolbetuximab (Vyloy) for HER2-negative, claudin-18.2 (CLDN18.2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinomas. It is the first CLDN18.2-targeted ...
The image crashes when you try to run forge in 1.12.2. [init] Running as uid=1000 gid=1000 with /data as 'drwxrwxr-x 2 1000 1000 4096 Aug 3 18:19 /data' [init] Resolving type given FORGE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results